Free Trial
TSE:HBP

Helix BioPharma (HBP) Stock Price, News & Analysis

Helix BioPharma logo
C$0.98 0.00 (0.00%)
As of 02/21/2025 03:29 PM Eastern

About Helix BioPharma Stock (TSE:HBP)

Key Stats

Today's Range
C$0.75
C$0.98
50-Day Range
C$0.78
C$1.00
52-Week Range
C$0.50
C$1.35
Volume
2,840 shs
Average Volume
1,839 shs
Market Capitalization
C$51.96 million
P/E Ratio
N/A
Dividend Yield
1.50%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

Receive HBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HBP Stock News Headlines

Helix BioPharma Reports Fiscal Loss, Refocuses Strategy
NVDA Crash Update
An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investors worrying – Is this the end of the great AI bull run?
HBP:CA Helix BioPharma Corp.
Helix Biopharma: Fiscal Q2 Earnings Snapshot
See More Headlines

HBP Stock Analysis - Frequently Asked Questions

Helix BioPharma's stock was trading at C$0.89 at the start of the year. Since then, HBP shares have increased by 10.1% and is now trading at C$0.98.
View the best growth stocks for 2025 here
.

Helix BioPharma Corp. (TSE:HBP) posted its quarterly earnings results on Thursday, October, 24th. The biopharmaceutical company reported ($0.11) EPS for the quarter.

Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Helix BioPharma investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Green Thumb Industries (GTBIF), Amplify Seymour Cannabis ETF (CNBS), Cenovus Energy (CVE), Enbridge (ENB) and Micron Technology (MU).

Company Calendar

Last Earnings
10/24/2024
Today
2/23/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Net Income
C$-50,548,392.71
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.09 per share
Book Value
C($0.14) per share

Miscellaneous

Free Float
N/A
Market Cap
C$51.96 million
Optionable
Not Optionable
Beta
-0.84
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (TSE:HBP) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners